TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T39716	Voltage-gated sodium channel alpha Nav1.5	D00PEH	Eltrombopag	Approved	135449332	C25H22N4O4	442.5	.	IC50 = 158489.32 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D01AZG	Risperidone	Approved	5073	C23H27FN4O2	410.5	CC1=C(C(=O)N2CCCCC2=N1)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F	IC50 = 102000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D03FLC	Lamotrigine	Approved	3878	C9H7Cl2N5	256.089	C1=CC(=C(C(=C1)Cl)Cl)C2=C(N=C(N=N2)N)N	IC50 = 62000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D03IGH	Darunavir	Approved	213039	C27H37N3O7S	547.7	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N	IC50 = 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D05MQK	Tadalafil	Approved	110635	C22H19N3O4	389.4	CN1CC(=O)N2[C@@H](C1=O)CC3=C([C@H]2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36	IC50 = 125892.54 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D09MWJ	Alfuzosin	Approved	2092	C19H27N5O4	389.4	CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC	IC50 = 199526.23 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0B3UJ	Paliperidone	Approved	115237	C23H27FN4O3	426.5	CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F	IC50 = 158489.32 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0C9SY	Vardenafil	Approved	135400189	C23H32N6O4S	488.6	.	IC50 = 199526.23 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0E4DW	Phenytoin	Approved	1775	C15H12N2O2	252.27	C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0E6XR	Dasatinib	Approved	3062316	C22H26ClN7O2S	488	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO	IC50 = 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0K3QS	Everolimus	Approved	6442177	C53H83NO14	958.2	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC	IC50 = 199526.23 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0L3MP	VRX496	Approved	64143	C32H45N3O4S	567.8	CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O	IC50 = 79432.82 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0O3FG	Desvenlafaxine	Approved	125017	C16H25NO2	263.37	CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O	IC50 = 199526.23 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0Q5UQ	Exjade	Approved	214348	C21H15N3O4	373.4	.	IC50 = 79432.82 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0U0VU	SILODOSIN	Approved	5312125	C25H32F3N3O4	495.5	C[C@H](CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F	IC50 = 63095.73 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0X4RN	Lidocaine	Approved	3676	C14H22N2O	234.34	CCN(CC)CC(=O)NC1=C(C=CC=C1C)C	IC50 = 108000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	D0A4UC	GS-6615	Phase 3	71183216	C21H16F3N3O3	415.4	C1COC2=C(C=C(C=C2)C3=CC=C(C=C3)OC(F)(F)F)C(=O)N1CC4=NC=CC=N4	IC50 = 52000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B08IER	N-[4-[2-[(5R)-5-(2,4-Difluorophenyl)-2-methyl-1,5-dihydro-2,4-benzodiazepin-3-yl]ethyl]phenyl]methanesulfonamide;hydrochloride	Investigative	54580954	C25H26ClF2N3O2S	506	CN1CC2=CC=CC=C2[C@@H](N=C1CCC3=CC=C(C=C3)NS(=O)(=O)C)C4=C(C=C(C=C4)F)F.Cl	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B0W6UZ	2-[1-[2-Hydroxy-3-(2-methoxyphenoxy)propyl]piperidin-4-yl]-3H-isoindol-1-one	Investigative	122196022	C23H28N2O4	396.5	COC1=CC=CC=C1OCC(CN2CCC(CC2)N3CC4=CC=CC=C4C3=O)O	IC50 = 77000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B1GA8X	Chembl4126528	Investigative	145963172	C22H29N3O2	367.5	C[C@@]12CCC(=O)C[C@@H]1C[C@H]([C@@H]2OC3=CC=C(C=C3)C#N)N4CCC[C@H](C4)N	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B26CVM	4-Methoxy-N-(2,4,6-trimethylphenyl)benzenesulfonamide	Investigative	743974	C16H19NO3S	305.4	CC1=CC(=C(C(=C1)C)NS(=O)(=O)C2=CC=C(C=C2)OC)C	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B5MGH8	Chembl4125756	Investigative	145963143	C22H31N3O2	369.5	C[C@]12CC[C@H](C[C@H]1C[C@H]([C@@H]2OC3=CC=C(C=C3)C#N)N4CCC[C@H](C4)N)O	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B6A1GJ	Chembl4126041	Investigative	145962956	C20H25N3O2	339.4	C1C[C@H](CN(C1)[C@@H]2C[C@@H]3[C@H]([C@H]2OC4=CC=C(C=C4)C#N)CCC3=O)N	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B6L8JK	1-[Amino(4-methylbenzoylimino)methyl]indoline	Investigative	11780892	C17H17N3O	279.34	CC1=CC=C(C=C1)C(=O)N=C(N)N2CCC3=CC=CC=C32	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B7GH3J	Chembl4130214	Investigative	145961840	C19H23N3O2	325.4	C1C[C@H](CN(C1)[C@@H]2C[C@@H]3[C@H]([C@H]2OC4=CC=C(C=C4)C#N)CC3=O)N	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B8JD7P	(E)-But-2-enedioic acid;N-[4-[[(5R)-2-methyl-5-phenyl-1,5-dihydro-2,4-benzodiazepin-3-yl]oxymethyl]phenyl]methanesulfonamide	Investigative	54580950	C28H29N3O7S	551.6	CN1CC2=CC=CC=C2[C@H](N=C1OCC3=CC=C(C=C3)NS(=O)(=O)C)C4=CC=CC=C4.C(=C/C(=O)O)\\C(=O)O	IC50 = 126000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B8R9GA	(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-pyrazolo[1,5-a]pyrimidin-5-ylphenyl)butanamide;2,2,2-trifluoroacetic acid	Investigative	11541314	C24H25F5N6O4	556.5	CN(C)C(=O)[C@@H](C1=CC=C(C=C1)C2=NC3=CC=NN3C=C2)[C@@H](C(=O)N4CCC(C4)(F)F)N.C(=O)(C(F)(F)F)O	IC50 = 60000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B9O1JK	Chembl4126435	Investigative	145955642	C26H36N4O2	436.6	C[C@]12CC/C(=C\\C(=O)N(C)C)/C[C@H]1C[C@H]([C@@H]2OC3=CC=C(C=C3)C#N)N4CCC[C@H](C4)N	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	B9X2YV	(2,3-Dimethylpiperidin-1-yl)-[2-(4-methylanilino)-1,3-thiazol-4-yl]methanone	Investigative	71818431	C18H23N3OS	329.5	CC1CCCN(C1C)C(=O)C2=CSC(=N2)NC3=CC=C(C=C3)C	IC50 = 50000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BDAK81	Chembl4126938	Investigative	145961922	C23H33N3O2	383.5	C[C@]12CCC(C[C@H]1C[C@H]([C@@H]2OC3=CC=C(C=C3)C#N)N4CCC[C@H](C4)N)(C)O	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BGQ0I1	(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-[4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]butanamide;2,2,2-trifluoroacetic acid	Investigative	11649741	C24H25F5N6O4	556.5	CN(C)C(=O)[C@@H](C1=CC=C(C=C1)C2=CN3C(=NC=N3)C=C2)[C@@H](C(=O)N4CCC(C4)(F)F)N.C(=O)(C(F)(F)F)O	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BHJ43T	N-[[5-[1-(2-Imidazol-1-ylethyl)indazol-3-yl]-1,2,4-oxadiazol-3-yl]methyl]benzamide	Investigative	52920492	C22H19N7O2	413.4	C1=CC=C(C=C1)C(=O)NCC2=NOC(=N2)C3=NN(C4=CC=CC=C43)CCN5C=CN=C5	IC50 = 69000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BI6KA8	6-[({1-[2-(7-Methoxy-2-oxoquinoxalin-1(2H)-yl)ethyl]piperidin-4-yl}amino)methyl]-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one	Investigative	15982534	C24H28N6O4	464.5	COC1=CC2=C(C=C1)N=CC(=O)N2CCN3CCC(CC3)NCC4=NC5=C(C=C4)OCC(=O)N5	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BM30AT	Chembl4129913	Investigative	145963706	C22H31N3O2	369.5	C[C@]12CC[C@@H](C[C@H]1C[C@H]([C@@H]2OC3=CC=C(C=C3)C#N)N4CCC[C@H](C4)N)O	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BN7D4P	3-(2-Aminopropoxy)-2,4-dimethylphenol	Investigative	3035569	C11H17NO2	195.26	CC1=C(C(=C(C=C1)O)C)OCC(C)N	IC50 = 174000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BPRX58	3,5-Dichloro-N-[[1-[[(4S)-2,2-dimethyloxan-4-yl]methyl]-4-fluoropiperidin-4-yl]methyl]benzamide	Investigative	24893979	C21H29Cl2FN2O2	431.4	CC1(C[C@H](CCO1)CN2CCC(CC2)(CNC(=O)C3=CC(=CC(=C3)Cl)Cl)F)C	IC50 = 84000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BR67AW	N-[4-[2-[(5S)-5-(2,4-Difluorophenyl)-2-methyl-1,5-dihydro-2,4-benzodiazepin-3-yl]ethyl]phenyl]methanesulfonamide;hydrochloride	Investigative	70697529	C25H26ClF2N3O2S	506	CN1CC2=CC=CC=C2[C@H](N=C1CCC3=CC=C(C=C3)NS(=O)(=O)C)C4=C(C=C(C=C4)F)F.Cl	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BSEF80	Auglurant	Investigative	60168069	C16H12FN5O2	325.3	CC1=CC(=CC(=N1)C(=O)NC2=NC=C(C=C2)F)OC3=CN=CN=C3	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BV3J9P	(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-[4-([1,2,4]triazolo[1,5-a]pyridin-7-yl)phenyl]butanamide;2,2,2-trifluoroacetic acid	Investigative	11613750	C24H25F5N6O4	556.5	CN(C)C(=O)[C@@H](C1=CC=C(C=C1)C2=CC3=NC=NN3C=C2)[C@@H](C(=O)N4CCC(C4)(F)F)N.C(=O)(C(F)(F)F)O	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BXG69T	Chembl4129805	Investigative	145962891	C22H27N3O2	365.5	C1C[C@H](CN(C1)[C@@H]2C[C@@H]3[C@H]4C[C@@H]([C@@H]3[C@H]2OC5=CC=C(C=C5)C#N)C(=O)C4)N	IC50 ~ 100000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BXU5K1	CID 56596233	Investigative	56596233	C22H16ClN5O3	433.8	CC1=NOC(=N1)CN2C(=O)N3C=C(C=CC3=N2)C4=CC=C(C=C4)OC5=CC=C(C=C5)Cl	IC50 = 134000 nM	Poor binder
T39716	Voltage-gated sodium channel alpha Nav1.5	BYFV19	N-[6-(Trifluoromethyl)pyridine-3-yl]-2-(trifluoromethyl)benzenesulfonamide	Investigative	118917669	C13H8F6N2O2S	370.27	C1=CC=C(C(=C1)C(F)(F)F)S(=O)(=O)NC2=CN=C(C=C2)C(F)(F)F	IC50 ~ 100000 nM	Poor binder